Join us at #ASCO24 as we present data highlighting important developments in cancer care using liquid biopsy to identify epigenomic biomarkers. Visit booth 28115 to learn more.
Guardant Health’s Post
More Relevant Posts
-
The surge in cancer instances highlights the crucial role radiotheranostics plays in transforming global healthcare. Per The Business Research Company’s Radiotheranostics Global Market Report 2023, Cancer Research UK reported 18 million new cancer cases, with projections foreseeing a staggering 54.9% increase by 2040, reaching 28 million cases annually. Understand how radiotheranostics medicines stand at the forefront, offering the promise of personalized treatment through diagnostic and therapeutic radionuclide probes. Explore our comprehensive report for an in-depth analysis radiotheranostics market: https://lnkd.in/dJP5P3Vu . . . #radiotheranostics #radiopharmaceuticals #targetedradiotreatmen #cancerresearch #tbrc #thebusinessresearchcompany #marketresearch #marketintelligence
To view or add a comment, sign in
-
For patients with an actionable mutation, biomarker testing may be a life-saving game-changer. Meet Dr Sydney Barned who was diagnosed with stage 4 non-small cell lung cancer at 33. Thanks to biomarker testing she was matched with a targeted therapy and her cancer went into remission. Six years later Dr Barned has finished her residency, gotten married and is able to fully enjoy her life doing all of the things she loves with family and friends. https://hubs.ly/Q01ZcdSs0 At Biofidelity, our goal is to make genomic analysis simpler, more efficient and cost effective so patients can get on life saving therapies quicker after diagnosis. Learn more by visiting https://hubs.ly/Q01ZcqPY0
Biomarker testing giving cancer patients new hope
cbsnews.com
To view or add a comment, sign in
-
I challenge you to listen to the latest edition of OvaView with Victoria Haverbusch and not get excited about #OvaWatch.This one-of-a-kind proprietary blood test has demonstrated its accuracy in assessing the risk of malignancy in women with an adnexal mass, a breakthrough by any measure. For far too long, a lack of confidence in non-invasive methods of assessing ovarian cancer risk has led us to resort to surgical intervention even though the vast majority of the masses turn out to be benign. Aspira Women's Health is going to change that. The use of #OvaWatch initial clinical assessment and ongoing mass monitoring can reduce unnecessary surgery and surgical menopause while simultaneously improving a clinician's ability to identify those patients that require additional care and clinical intervention. #obgyn #innovation #dx #ovariancancer #gynecology #womenshealth #nursepractitioner
Introducing a new “OvaView” summary featuring Victoria Haverbusch, our expert in risk assessment. Explore the latest advancements in biomarker technology for assessing ovarian cancer risk in a concise video and gain valuable insights to enrich your clinical decision-making process. #OvaView #AspiraWomensHealth #OvarianCancerAwareness #OvarianCancer #WomensHealth
To view or add a comment, sign in
-
Theralase Technologies (TSXV: TLT) CEO Roger DuMoulin-White joined Steve Darling from Proactive to share details of an update on the company's Phase II Non-Muscle Invasive #BladderCancer clinical study during an interview with Steve Darling from Proactive. DuMoulin-White shared the significant findings from the study, revealing that it has provided the primary study treatment to 63 patients. The interim clinical data from Study II shows promising results, with a Complete Response (CR) rate of 54% at 6 months, 38% at 12 months, and 37% at 15 months. These CR rates surpass the guidelines set by the International Bladder Cancer Group (IBCG). Additionally, at the 90 Day Assessment Visit, 56% of Evaluable Patients achieved a CR, and 63% achieved a Total Response (CR + IR). At 450 days, 37% achieved a CR, and 41% achieved a TR. Watch at #Proactive #ProactiveInvestors #TSXV #OTCQB #TLT #TLTFF http://ow.ly/YLin10598yw
Theralase Technologies shares update on Phase II Bladder Cancer study
proactiveinvestors.com
To view or add a comment, sign in
-
💜Today marks #RareDiseaseDay, shedding light on the challenges faced by those with uncommon conditions. "Rare cancers remain also rarely studied, and that's why we cannot stop working towards finding more options for the patients." says kishor Bhatia, Lantern Pharma Inc. (Nasdaq: LTRN)'s Chief scientific officer. Lantern Pharma is dedicated to pioneering solutions for patients with rare cancers, starting with our drug candidate, LP-184 and LP-284. Discover how Lantern pharma is leveraging AI for rare cancer treatments at www.lanternpharma.com. #RareCancerAwareness #AdvocacyMatters
To view or add a comment, sign in
-
It was a true pleasure joining Hannah Kuchler, Dan Vahdat and Dick Sundh today in a conversation about the rise of precision medicine across different therapeutic areas at #FTPharma's Global Pharma and Biotech Summit 2023. In cancer care, understanding our future patient population will be key. We will be seeing more patients suffering from cancer. Novel screening methods will enable the diagnosis of more patients at an earlier stage of their disease. At the same time, we will be treating more early-onset cancer patients (age at first diagnosis <50). The challenge of resistance to treatment will further increase. At #teambayer we are committed to developing more efficacious, better tolerable (“kinder”) medicines, tailored for (today's and future) patients. #precisiondrugdevelopment #OncologyInspired #cancerresearch
To view or add a comment, sign in
-
-
A HUGE THANK YOU to all oncologists, researchers and biopharma companies who have worked closely with us this year. Thank you for your support and confidence in Guardant Health’s comprehensive genomic profiling tests which are transforming cancer care across all stages of the disease. As we move into 2024, we look forward to your continued support in guiding treatment decisions for patients with cancer in Asia, Middle East and Africa. Patient centricity is the heart of all that we do. We serve each patient like a family member. Visit us at https://lnkd.in/gHNdYtQN to find out more about our comprehensive genomic profiling tests which can help guide treatment decisions for patients with cancer. #guardanthealth #guardanthealthamea #thankyou #oncologists #medicaloncologists #researchers #biopharma #cancerpatients #puttingpatientsfirst #guardant360 #guardant360tissuenext #guardantreveal #guardantresponse #shield #nextgenerationsequencing #NGS #comprehensivegenomicprofiling #liquidissolid
To view or add a comment, sign in
-
-
🌐📊 Cancer Diagnostics Market Surges to USD 188.43 Billion by 2031! 📈💡 Exciting news from Cogentix Research! The cancer diagnostics market is projected to skyrocket to a staggering USD 188.43 billion by 2031, fueled by a robust 6.77% CAGR. This significant growth underscores the vital advancements and innovations in cancer diagnostics, paving the way for improved patient outcomes and enhanced healthcare solutions. Stay tuned for more insights and in-depth analysis from our expert team! #CancerDiagnostics #MarketGrowth #CogentixResearch #HealthcareInnovation #MedicalAdvancements #ResearchInsights
To view or add a comment, sign in
-
-
#RWD is a versatile tool advancing multiple aspects of #cancerresearch and care. BC Platforms enables our customers to leverage #bladdercancer #data to support their specific research projects. In bladder cancer specifically, RWD is being leveraged in various ways to advance research and knowledge: ➡️Understanding treatment patterns ➡️Assessing clinical outcomes ➡️Recruiting for clinical trials ➡️Evaluating biomarker use ➡️Modeling costs Learn more: https://bit.ly/44fX4TS
Primer Series: The Role of Real-World Data in Bladder Cancer Research - BC Platforms
https://www.bcplatforms.com
To view or add a comment, sign in
-
📢 New article in Oncology Issues (July 2023) ACCC shares a look at the current NTRK testing landscape and identifies effective ways to optimize comprehensive biomarker testing in practice. Gathered by a series of focus groups with multidisciplinary care team members from cancer programs nationwide, this article also explores barriers to testing and common misconceptions related to NTRK testing. 🔗 Read the entire article, “Emerging Biomarkers: Innovative Therapies for Rare Disease,” by Joseph Kim, MD, MPH, MBA, FACHEF. https://lnkd.in/eMJThrGy #Biomarkers #CancerCare #RareDisease
To view or add a comment, sign in
-